Industry News (Clinical Trials)

Three New In Vivo Gene Therapy Trials Initiated

Published in Cancer Weekly, November 20th, 1995

Introgen Therapeutics, Inc., Austin, Texas, announced that researchers at the University of Texas M.D. Anderson Cancer Center, Houston, have initiated three new in vivo gene therapy studies for the treatment of cancer.

Introgen, which maintains a broad, exclusive license to numerous technologies developed by key scientists at M.D. Anderson, now has the largest in vivo cancer portfolio in the field of gene therapy.

The study researchers have injected the first patients ever with a p53/adenoviral gene therapy product for the treatment of non-resectable and resectable head and neck cancer and non-small cell lung cancer (NSCLC).

"Our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-11-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry